Central Pharmaceuticals Ltd. (DSE:CENTRALPHL)
Bangladesh · Delayed Price · Currency is BDT 9.30
0.00 (0.00%)
At close: Jun 16, 2026
Central Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 36.1 | 33.06 | 29.6 | 29.33 | 26 | 148.15 | |
Revenue Growth (YoY) | - | 11.68% | 0.93% | 12.81% | -82.45% | 5.75% |
Cost of Revenue | 47.52 | 44.19 | 50.21 | 58.36 | 63.58 | 118.89 |
Gross Profit | -11.43 | -11.13 | -20.61 | -29.03 | -37.58 | 29.27 |
Selling, General & Admin | 11.85 | 11.57 | 16.65 | 18.83 | 15.77 | 22.45 |
Other Operating Expenses | - | - | 0.44 | - | - | - |
Operating Expenses | 11.85 | 11.57 | 17.09 | 18.83 | 15.77 | 22.45 |
Operating Income | -23.27 | -22.7 | -37.7 | -47.86 | -53.35 | 6.82 |
Interest Expense | - | - | - | - | -17.36 | -21.36 |
Interest & Investment Income | 0.01 | 0.01 | 0.01 | 0 | 0 | 0.01 |
Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0.01 | -0.11 | -0.09 |
EBT Excluding Unusual Items | -23.28 | -22.7 | -37.71 | -47.87 | -70.82 | -14.63 |
Asset Writedown | - | - | -10.59 | - | - | - |
Pretax Income | -23.28 | -22.7 | -48.3 | -47.87 | -70.82 | -14.63 |
Income Tax Expense | -1.6 | -0.72 | -5.88 | -3.91 | -2.57 | -6.16 |
Net Income | -21.67 | -21.98 | -42.42 | -43.96 | -68.25 | -8.47 |
Net Income to Common | -21.67 | -21.98 | -42.42 | -43.96 | -68.25 | -8.47 |
Shares Outstanding (Basic) | 120 | 120 | 120 | 120 | 120 | 120 |
Shares Outstanding (Diluted) | 120 | 120 | 120 | 120 | 120 | 120 |
Shares Change (YoY) | 0.69% | - | - | - | - | - |
EPS (Basic) | -0.18 | -0.18 | -0.35 | -0.37 | -0.57 | -0.07 |
EPS (Diluted) | -0.18 | -0.18 | -0.35 | -0.37 | -0.57 | -0.07 |
Free Cash Flow | -0.02 | -0.52 | 2.97 | -0.33 | -1.12 | -4.78 |
Free Cash Flow Per Share | - | -0.00 | 0.03 | -0.00 | -0.01 | -0.04 |
Gross Margin | -31.66% | -33.66% | -69.62% | -98.99% | -144.57% | 19.75% |
Operating Margin | -64.48% | -68.66% | -127.37% | -163.18% | -205.21% | 4.60% |
Profit Margin | -60.04% | -66.49% | -143.31% | -149.88% | -262.51% | -5.72% |
Free Cash Flow Margin | -0.07% | -1.57% | 10.02% | -1.11% | -4.31% | -3.22% |
EBITDA | 2.83 | -1.08 | -24.25 | -21.11 | -23.59 | 39.71 |
EBITDA Margin | 7.84% | -3.28% | -81.92% | -71.98% | -90.75% | 26.80% |
D&A For EBITDA | 26.1 | 21.61 | 13.45 | 26.75 | 29.76 | 32.89 |
EBIT | -23.27 | -22.7 | -37.7 | -47.86 | -53.35 | 6.82 |
EBIT Margin | -64.48% | -68.66% | -127.37% | -163.18% | -205.21% | 4.60% |